Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib Combined With Bevacizumab in Platinum-sensitive Recurrent Ovarian Cancer
NCT05551208Phase 2Recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Aug 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluzoparib in ovarian cancer, sponsored by Chongqing University Cancer Hospital. Started Aug 2022; status: recruiting.
02
Drugs
fluzoparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05551208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05551208.